The beneficial effect of prophylactic hydrocortisone treatment in extremely preterm infants improves upon adjustment of the baseline characteristics.

ABSTRACT:

Background

Prophylactic low-dose hydrocortisone (HC) was found to improve survival without bronchopulmonary dysplasia (BPD) in extremely preterm infants. However, appropriately adjusting for baseline risks of BPD or death might substantially increase the precision of the HC effect size.

Methods

We conducted a secondary analysis of the PREMILOC trial. The treatment effect was evaluated on the primary endpoint through a covariance analysis ANCOVA, adjusting for the baseline covariates using a mixed linear model. Several sensitivity analyses were conducted to assess the potential heterogeneity of the treatment effect across centers and subpopulations.

Results

The interaction between treatment group and baseline risk for BPD or death was not statistically significant (p =

SUBMITTER: Baud O 

PROVIDER: S-EPMC10798883 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature